You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

February 23, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Move over Sovaldi: Could PCSK9 inhibitors be a bigger cost challenge?

The introduction of high-cost, high-use PCSK9 inhibitors (proprotein convertase subtilisin/kexin 9) enzyme inhibitors to treat high cholesterol, takes the industry step closer to a future where "healthcare costs break the bank," according to industry insiders. » Details

FDA expands approval of Revlimid to include newly diagnosed multiple myeloma

FDA expanded approval of lenalidomide (Revlimid, Celgene) for the treatment of multiple myeloma. » More

Continuing Education

New and emerging therapies for the treatment of diabetes

This month and next month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to discuss new and emerging medications for the treatment of diabetes.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT15-WKX27.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Medication therapy can increase long-term success for smokers who want to cut back first: Study

A study of more than 1,500 cigarette smokers who were not ready to quit smoking but were willing to cut back on cigarette consumption and combine their approach with varenicline (Chantix, Pfizer) increased their long-term success of quitting smoking, according to study published in the Journal of the American Medical Association. » Read more.

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 
Advertisement

RELATED ARTICLES

CVS Health commits to Gilead's hepatitis C drugs

Proteasome inhibitor meets primary end point of improvement in PFS in relapsed or refractory multiple myeloma

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group